menu
    • menu

    Company profile for ImmunoGenesis

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    We are rapidly translating the most cutting-edge discoveries from academic tumor immunology into drugs optimized for treating the majority of patients who have "cold" cancers refractory to currently available immunotherapy. Immunogenesis is focused on developing a pipeline of drugs that, in combination, will synergize to address the critical ingredients for effective immunity against "cold" tumors: 1) Generation of sufficient...
    We are rapidly translating the most cutting-edge discoveries from academic tumor immunology into drugs optimized for treating the majority of patients who have "cold" cancers refractory to currently available immunotherapy. Immunogenesis is focused on developing a pipeline of drugs that, in combination, will synergize to address the critical ingredients for effective immunity against "cold" tumors: 1) Generation of sufficient anti-tumor T cells; 2) protection and expansion of those cells in the tumor; and 3) reduction in hostile tumor metabolism.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ImmunoGenesisUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    909 Fannin St Suite 2000 Houston, TX 77010
    Telephone
    Telephone
    (713) 276-7600
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.immunogenesis.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Immunogenesis Gets $10.8M Grant To Advance IMGS-001
    Immunogenesis Gets $10.8M Grant To Advance IMGS-001

    04 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/immunogenesis-receives-10-8-million-grant-from-the-cancer-prevention--research-institute-of-texas-cprit-to-accelerate-the-clinical-development-of-imgs-001-for-patients-with-immune-excluded-tumors-with-high-unmet-need-302632467.html

    PR NEWSWIRE
    04 Dec 2025
    Share Share
    ImmunoGenesis Forms New Scientific Advisory Board
    ImmunoGenesis Forms New Scientific Advisory Board

    01 Jul 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/immunogenesis-announces-the-formation-of-scientific-advisory-board-302495832.html

    PR NEWSWIRE
    01 Jul 2025
    Share Share
    ImmunoGenesis to present IMGS-001 Study Updates at ASCO 2025
    ImmunoGenesis to present IMGS-001 Study Updates at ASCO 2025

    30 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/immunogenesis-to-present-imgs-001-phase-1a1b-clinical-study-updates-at-the-2025-american-society-of-clinical-oncology-asco-annual-meeting-302469451.html

    PR NEWSWIRE
    30 May 2025
    Share Share
    ImmunoGenesis doses first patient in Phase 1/2 trial of IMGS-101
    ImmunoGenesis doses first patient in Phase 1/2 trial of IMGS-101

    06 Mar 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/immunogenesis-doses-first-patient-in-phase-12-clinical-trial-of-imgs-101-in-combination-with-balstilimab-anti-pd-1-and-zalifrelimab-anti-ctla-4-in-relapsed-or-refractory-advanced-prostate-pancreatic-and-hpv--head--neck-t-302393719.html

    PR NEWSWIRE
    06 Mar 2025
    Share Share
    PolyPid Announces R&D Collab with ImmunoGenesis for Cancer Therapy
    PolyPid Announces R&D Collab with ImmunoGenesis for Cancer Therapy

    11 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/11/2995254/0/en/PolyPid-Announces-Research-and-Development-Collaboration-with-ImmunoGenesis-Leveraging-PLEX-Technology-to-Enhance-Cancer-Immunotherapy.html

    GLOBENEWSWIRE
    11 Dec 2024
    Share Share
    ImmunoGenesis Doses First Patient in Phase 1a/1b Clinical Trial of IMGS-001
    ImmunoGenesis Doses First Patient in Phase 1a/1b Clinical Trial of IMGS-001

    28 Sep 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/immunogenesis-doses-first-patient-in-phase-1a1b-clinical-trial-of-imgs-001-in-relapsed-or-refractory-advanced-solid-tumors-301941636.html

    PR NEWSWIRE
    28 Sep 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search